Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity

1 The full therapeutic potential of the main immunosuppressive drug, cyclosporin A (CsA), is limited because of its side effects, namely nephrotoxicity and hypertension. Several lines of evidence suggest that the origin of both side effects could be CsA‐induced vasoconstriction. However, the underly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 1996-06, Vol.118 (4), p.885-892
Hauptverfasser: Russo, A. Lo, Passaquin, A.‐C., André, P., Skutella, M., Rüegg, U.T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 892
container_issue 4
container_start_page 885
container_title British journal of pharmacology
container_volume 118
creator Russo, A. Lo
Passaquin, A.‐C.
André, P.
Skutella, M.
Rüegg, U.T.
description 1 The full therapeutic potential of the main immunosuppressive drug, cyclosporin A (CsA), is limited because of its side effects, namely nephrotoxicity and hypertension. Several lines of evidence suggest that the origin of both side effects could be CsA‐induced vasoconstriction. However, the underlying molecular mechanisms are not well understood. 2 Diameter measurements of rat isolated mesenteric arteries showed an increase in noradrenaline‐ and [Arg]8vasopressin‐induced vasoconstriction when arteries were pretreated with CsA. 3 Measurements in cultured vascular smooth muscle cells (VSMC) of either cytosolic calcium concentration or of 45Ca2+ efflux showed that CsA potentiated the calcium influx to several vasoconstrictor hormones: [Arg]8vasopressin, angiotensin II, endothelin‐1 and 5‐hydroxytryptamine. On the other hand, 45Ca2+ efflux in response to thapsigargin, which depletes calcium from intracellular pools, was not potentiated by CsA. 45Ca2+ uptake was not altered by CsA or by any of the analogues tested. 4 Time‐course studies in cultured VSMC showed that maximal CsA‐induced Ca2+ potentiation occurred after ca. 20 h and this effect was reversed over approximately the next 20 h. 5 To investigate the possible role played by the known intracellular targets of CsA, namely cyclophilin and calcineurin, CsA derivatives with variable potencies with respect to their immunosuppressive activity, were tested on the calcium influx to [Arg]8vasopressin. Derivatives devoid of immunosuppressive activity (cyclosporin H, PSC‐833) potentiated calcium signalling, while the potent immunosuppressant, FK520, a close derivative of FK506, and MeVal4CsA, an antagonist of the immunosuppressive effect of CsA did not. The latter compound was unable to reverse the calcium potentiating effect of CsA. 6 Our results show that CsA increases the calcium influx to vasoconstrictor hormones in smooth muscle cells, which presumably increases vasoconstriction. Loading of the intracellular calcium pools appears not to be involved. Experiments with derivatives of CsA and FK520 suggest that interactions with cyclophilins and calcineurin are not the mechanism involved. This indicates, for the first time, that the immunosuppressive activity can be dissociated from the calcium potentiating effect of CsA in vascular smooth muscle.
doi_str_mv 10.1111/j.1476-5381.1996.tb15482.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1909504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16117930</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5382-22641d59baf49d03e623ef201a2a3a28aee887a2f4cc280b2bf23fc6afecb23e3</originalsourceid><addsrcrecordid>eNqVkd9uFCEUxompqWv1EUyIaXo3IzD_mF6Y1qa1Jk30Qq_JGRZaVgZGmFm77-BDl-lONnopCYHk-52Pc_gQek9JTtP6sMlp2dRZVXCa07at87GjVclZ_vgCrQ7SEVoRQpqMUs5fodcxbghJYlMdo2PetG1V8RX6c621kiP2GsudtD4OPhiHLzG4ddpg_f2kIvYuyaOP3hqJJVhppv4Z2UL00rs4BiNH4905HnyMprMKW5A_Z9-gLMxSfDADHj02fT85H6dhCCqhW4UhlW7NuHuDXmqwUb1dzhP04-b6-9Vtdvf185ery7tMprlYxlhd0nXVdqDLdk0KVbNCaUYoMCiAcVCK8waYLqVknHSs06zQsoY0aZfQ4gR93PsOU9ertVRuDGDFEEwPYSc8GPGv4syDuPdbQVvSVqRMBmeLQfC_0v-MojdRKmvBKT9FQWtKm7YgCTzfgzKkbwlKHx6hRMxZio2YAxNzYGLOUixZisdU_O7vNg-lS3hJP110iCkTHcBJEw9YQVldkSphF3vst7Fq9x8NiE_fbp-vxRMM5sJj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16117930</pqid></control><display><type>article</type><title>Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity</title><source>PubMed (Medline)</source><source>MEDLINE</source><source>Wiley Online Library Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Russo, A. Lo ; Passaquin, A.‐C. ; André, P. ; Skutella, M. ; Rüegg, U.T.</creator><creatorcontrib>Russo, A. Lo ; Passaquin, A.‐C. ; André, P. ; Skutella, M. ; Rüegg, U.T.</creatorcontrib><description>1 The full therapeutic potential of the main immunosuppressive drug, cyclosporin A (CsA), is limited because of its side effects, namely nephrotoxicity and hypertension. Several lines of evidence suggest that the origin of both side effects could be CsA‐induced vasoconstriction. However, the underlying molecular mechanisms are not well understood. 2 Diameter measurements of rat isolated mesenteric arteries showed an increase in noradrenaline‐ and [Arg]8vasopressin‐induced vasoconstriction when arteries were pretreated with CsA. 3 Measurements in cultured vascular smooth muscle cells (VSMC) of either cytosolic calcium concentration or of 45Ca2+ efflux showed that CsA potentiated the calcium influx to several vasoconstrictor hormones: [Arg]8vasopressin, angiotensin II, endothelin‐1 and 5‐hydroxytryptamine. On the other hand, 45Ca2+ efflux in response to thapsigargin, which depletes calcium from intracellular pools, was not potentiated by CsA. 45Ca2+ uptake was not altered by CsA or by any of the analogues tested. 4 Time‐course studies in cultured VSMC showed that maximal CsA‐induced Ca2+ potentiation occurred after ca. 20 h and this effect was reversed over approximately the next 20 h. 5 To investigate the possible role played by the known intracellular targets of CsA, namely cyclophilin and calcineurin, CsA derivatives with variable potencies with respect to their immunosuppressive activity, were tested on the calcium influx to [Arg]8vasopressin. Derivatives devoid of immunosuppressive activity (cyclosporin H, PSC‐833) potentiated calcium signalling, while the potent immunosuppressant, FK520, a close derivative of FK506, and MeVal4CsA, an antagonist of the immunosuppressive effect of CsA did not. The latter compound was unable to reverse the calcium potentiating effect of CsA. 6 Our results show that CsA increases the calcium influx to vasoconstrictor hormones in smooth muscle cells, which presumably increases vasoconstriction. Loading of the intracellular calcium pools appears not to be involved. Experiments with derivatives of CsA and FK520 suggest that interactions with cyclophilins and calcineurin are not the mechanism involved. This indicates, for the first time, that the immunosuppressive activity can be dissociated from the calcium potentiating effect of CsA in vascular smooth muscle.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/j.1476-5381.1996.tb15482.x</identifier><identifier>PMID: 8799558</identifier><identifier>CODEN: BJPCBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>45Ca2+ efflux ; Adrenergic alpha-Agonists - pharmacology ; Amino Acid Isomerases - pharmacology ; Animals ; Biological and medical sciences ; Calcineurin ; Calcium - metabolism ; Calmodulin-Binding Proteins - pharmacology ; Carrier Proteins - pharmacology ; Cyclosporin A ; Cyclosporine - adverse effects ; Cyclosporine - pharmacology ; cyclosporins ; Dose-Response Relationship, Drug ; Enzyme Inhibitors - pharmacology ; fura‐2 ; Hypertension ; hypertensive side effect ; Immunomodulators ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - pharmacology ; intracellular calcium ; Male ; Medical sciences ; mesenteric arteries ; Mesenteric Arteries - drug effects ; Muscle, Smooth, Vascular - drug effects ; Norepinephrine - pharmacology ; Peptidylprolyl Isomerase ; Pharmacology. Drug treatments ; Phosphoprotein Phosphatases - pharmacology ; Rats ; Rats, Inbred WKY ; smooth muscle cells ; Thapsigargin - pharmacology ; Vasoconstriction - drug effects ; vasoconstrictor activity ; Vasoconstrictor Agents - pharmacology ; Vasopressins - pharmacology</subject><ispartof>British journal of pharmacology, 1996-06, Vol.118 (4), p.885-892</ispartof><rights>1996 British Pharmacological Society</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5382-22641d59baf49d03e623ef201a2a3a28aee887a2f4cc280b2bf23fc6afecb23e3</citedby><cites>FETCH-LOGICAL-c5382-22641d59baf49d03e623ef201a2a3a28aee887a2f4cc280b2bf23fc6afecb23e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1909504/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1909504/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1416,27922,27923,45572,45573,53789,53791</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3126505$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8799558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Russo, A. Lo</creatorcontrib><creatorcontrib>Passaquin, A.‐C.</creatorcontrib><creatorcontrib>André, P.</creatorcontrib><creatorcontrib>Skutella, M.</creatorcontrib><creatorcontrib>Rüegg, U.T.</creatorcontrib><title>Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>1 The full therapeutic potential of the main immunosuppressive drug, cyclosporin A (CsA), is limited because of its side effects, namely nephrotoxicity and hypertension. Several lines of evidence suggest that the origin of both side effects could be CsA‐induced vasoconstriction. However, the underlying molecular mechanisms are not well understood. 2 Diameter measurements of rat isolated mesenteric arteries showed an increase in noradrenaline‐ and [Arg]8vasopressin‐induced vasoconstriction when arteries were pretreated with CsA. 3 Measurements in cultured vascular smooth muscle cells (VSMC) of either cytosolic calcium concentration or of 45Ca2+ efflux showed that CsA potentiated the calcium influx to several vasoconstrictor hormones: [Arg]8vasopressin, angiotensin II, endothelin‐1 and 5‐hydroxytryptamine. On the other hand, 45Ca2+ efflux in response to thapsigargin, which depletes calcium from intracellular pools, was not potentiated by CsA. 45Ca2+ uptake was not altered by CsA or by any of the analogues tested. 4 Time‐course studies in cultured VSMC showed that maximal CsA‐induced Ca2+ potentiation occurred after ca. 20 h and this effect was reversed over approximately the next 20 h. 5 To investigate the possible role played by the known intracellular targets of CsA, namely cyclophilin and calcineurin, CsA derivatives with variable potencies with respect to their immunosuppressive activity, were tested on the calcium influx to [Arg]8vasopressin. Derivatives devoid of immunosuppressive activity (cyclosporin H, PSC‐833) potentiated calcium signalling, while the potent immunosuppressant, FK520, a close derivative of FK506, and MeVal4CsA, an antagonist of the immunosuppressive effect of CsA did not. The latter compound was unable to reverse the calcium potentiating effect of CsA. 6 Our results show that CsA increases the calcium influx to vasoconstrictor hormones in smooth muscle cells, which presumably increases vasoconstriction. Loading of the intracellular calcium pools appears not to be involved. Experiments with derivatives of CsA and FK520 suggest that interactions with cyclophilins and calcineurin are not the mechanism involved. This indicates, for the first time, that the immunosuppressive activity can be dissociated from the calcium potentiating effect of CsA in vascular smooth muscle.</description><subject>45Ca2+ efflux</subject><subject>Adrenergic alpha-Agonists - pharmacology</subject><subject>Amino Acid Isomerases - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Calcineurin</subject><subject>Calcium - metabolism</subject><subject>Calmodulin-Binding Proteins - pharmacology</subject><subject>Carrier Proteins - pharmacology</subject><subject>Cyclosporin A</subject><subject>Cyclosporine - adverse effects</subject><subject>Cyclosporine - pharmacology</subject><subject>cyclosporins</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>fura‐2</subject><subject>Hypertension</subject><subject>hypertensive side effect</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>intracellular calcium</subject><subject>Male</subject><subject>Medical sciences</subject><subject>mesenteric arteries</subject><subject>Mesenteric Arteries - drug effects</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Norepinephrine - pharmacology</subject><subject>Peptidylprolyl Isomerase</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphoprotein Phosphatases - pharmacology</subject><subject>Rats</subject><subject>Rats, Inbred WKY</subject><subject>smooth muscle cells</subject><subject>Thapsigargin - pharmacology</subject><subject>Vasoconstriction - drug effects</subject><subject>vasoconstrictor activity</subject><subject>Vasoconstrictor Agents - pharmacology</subject><subject>Vasopressins - pharmacology</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkd9uFCEUxompqWv1EUyIaXo3IzD_mF6Y1qa1Jk30Qq_JGRZaVgZGmFm77-BDl-lONnopCYHk-52Pc_gQek9JTtP6sMlp2dRZVXCa07at87GjVclZ_vgCrQ7SEVoRQpqMUs5fodcxbghJYlMdo2PetG1V8RX6c621kiP2GsudtD4OPhiHLzG4ddpg_f2kIvYuyaOP3hqJJVhppv4Z2UL00rs4BiNH4905HnyMprMKW5A_Z9-gLMxSfDADHj02fT85H6dhCCqhW4UhlW7NuHuDXmqwUb1dzhP04-b6-9Vtdvf185ery7tMprlYxlhd0nXVdqDLdk0KVbNCaUYoMCiAcVCK8waYLqVknHSs06zQsoY0aZfQ4gR93PsOU9ertVRuDGDFEEwPYSc8GPGv4syDuPdbQVvSVqRMBmeLQfC_0v-MojdRKmvBKT9FQWtKm7YgCTzfgzKkbwlKHx6hRMxZio2YAxNzYGLOUixZisdU_O7vNg-lS3hJP110iCkTHcBJEw9YQVldkSphF3vst7Fq9x8NiE_fbp-vxRMM5sJj</recordid><startdate>199606</startdate><enddate>199606</enddate><creator>Russo, A. Lo</creator><creator>Passaquin, A.‐C.</creator><creator>André, P.</creator><creator>Skutella, M.</creator><creator>Rüegg, U.T.</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>199606</creationdate><title>Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity</title><author>Russo, A. Lo ; Passaquin, A.‐C. ; André, P. ; Skutella, M. ; Rüegg, U.T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5382-22641d59baf49d03e623ef201a2a3a28aee887a2f4cc280b2bf23fc6afecb23e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>45Ca2+ efflux</topic><topic>Adrenergic alpha-Agonists - pharmacology</topic><topic>Amino Acid Isomerases - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Calcineurin</topic><topic>Calcium - metabolism</topic><topic>Calmodulin-Binding Proteins - pharmacology</topic><topic>Carrier Proteins - pharmacology</topic><topic>Cyclosporin A</topic><topic>Cyclosporine - adverse effects</topic><topic>Cyclosporine - pharmacology</topic><topic>cyclosporins</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>fura‐2</topic><topic>Hypertension</topic><topic>hypertensive side effect</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>intracellular calcium</topic><topic>Male</topic><topic>Medical sciences</topic><topic>mesenteric arteries</topic><topic>Mesenteric Arteries - drug effects</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Norepinephrine - pharmacology</topic><topic>Peptidylprolyl Isomerase</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphoprotein Phosphatases - pharmacology</topic><topic>Rats</topic><topic>Rats, Inbred WKY</topic><topic>smooth muscle cells</topic><topic>Thapsigargin - pharmacology</topic><topic>Vasoconstriction - drug effects</topic><topic>vasoconstrictor activity</topic><topic>Vasoconstrictor Agents - pharmacology</topic><topic>Vasopressins - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Russo, A. Lo</creatorcontrib><creatorcontrib>Passaquin, A.‐C.</creatorcontrib><creatorcontrib>André, P.</creatorcontrib><creatorcontrib>Skutella, M.</creatorcontrib><creatorcontrib>Rüegg, U.T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Russo, A. Lo</au><au>Passaquin, A.‐C.</au><au>André, P.</au><au>Skutella, M.</au><au>Rüegg, U.T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>1996-06</date><risdate>1996</risdate><volume>118</volume><issue>4</issue><spage>885</spage><epage>892</epage><pages>885-892</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><coden>BJPCBM</coden><abstract>1 The full therapeutic potential of the main immunosuppressive drug, cyclosporin A (CsA), is limited because of its side effects, namely nephrotoxicity and hypertension. Several lines of evidence suggest that the origin of both side effects could be CsA‐induced vasoconstriction. However, the underlying molecular mechanisms are not well understood. 2 Diameter measurements of rat isolated mesenteric arteries showed an increase in noradrenaline‐ and [Arg]8vasopressin‐induced vasoconstriction when arteries were pretreated with CsA. 3 Measurements in cultured vascular smooth muscle cells (VSMC) of either cytosolic calcium concentration or of 45Ca2+ efflux showed that CsA potentiated the calcium influx to several vasoconstrictor hormones: [Arg]8vasopressin, angiotensin II, endothelin‐1 and 5‐hydroxytryptamine. On the other hand, 45Ca2+ efflux in response to thapsigargin, which depletes calcium from intracellular pools, was not potentiated by CsA. 45Ca2+ uptake was not altered by CsA or by any of the analogues tested. 4 Time‐course studies in cultured VSMC showed that maximal CsA‐induced Ca2+ potentiation occurred after ca. 20 h and this effect was reversed over approximately the next 20 h. 5 To investigate the possible role played by the known intracellular targets of CsA, namely cyclophilin and calcineurin, CsA derivatives with variable potencies with respect to their immunosuppressive activity, were tested on the calcium influx to [Arg]8vasopressin. Derivatives devoid of immunosuppressive activity (cyclosporin H, PSC‐833) potentiated calcium signalling, while the potent immunosuppressant, FK520, a close derivative of FK506, and MeVal4CsA, an antagonist of the immunosuppressive effect of CsA did not. The latter compound was unable to reverse the calcium potentiating effect of CsA. 6 Our results show that CsA increases the calcium influx to vasoconstrictor hormones in smooth muscle cells, which presumably increases vasoconstriction. Loading of the intracellular calcium pools appears not to be involved. Experiments with derivatives of CsA and FK520 suggest that interactions with cyclophilins and calcineurin are not the mechanism involved. This indicates, for the first time, that the immunosuppressive activity can be dissociated from the calcium potentiating effect of CsA in vascular smooth muscle.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>8799558</pmid><doi>10.1111/j.1476-5381.1996.tb15482.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 1996-06, Vol.118 (4), p.885-892
issn 0007-1188
1476-5381
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1909504
source PubMed (Medline); MEDLINE; Wiley Online Library Journals; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects 45Ca2+ efflux
Adrenergic alpha-Agonists - pharmacology
Amino Acid Isomerases - pharmacology
Animals
Biological and medical sciences
Calcineurin
Calcium - metabolism
Calmodulin-Binding Proteins - pharmacology
Carrier Proteins - pharmacology
Cyclosporin A
Cyclosporine - adverse effects
Cyclosporine - pharmacology
cyclosporins
Dose-Response Relationship, Drug
Enzyme Inhibitors - pharmacology
fura‐2
Hypertension
hypertensive side effect
Immunomodulators
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - pharmacology
intracellular calcium
Male
Medical sciences
mesenteric arteries
Mesenteric Arteries - drug effects
Muscle, Smooth, Vascular - drug effects
Norepinephrine - pharmacology
Peptidylprolyl Isomerase
Pharmacology. Drug treatments
Phosphoprotein Phosphatases - pharmacology
Rats
Rats, Inbred WKY
smooth muscle cells
Thapsigargin - pharmacology
Vasoconstriction - drug effects
vasoconstrictor activity
Vasoconstrictor Agents - pharmacology
Vasopressins - pharmacology
title Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A23%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20cyclosporin%20A%20and%20analogues%20on%20cytosolic%20calcium%20and%20vasoconstriction:%20possible%20lack%20of%20relationship%20to%20immunosuppressive%20activity&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Russo,%20A.%20Lo&rft.date=1996-06&rft.volume=118&rft.issue=4&rft.spage=885&rft.epage=892&rft.pages=885-892&rft.issn=0007-1188&rft.eissn=1476-5381&rft.coden=BJPCBM&rft_id=info:doi/10.1111/j.1476-5381.1996.tb15482.x&rft_dat=%3Cproquest_pubme%3E16117930%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16117930&rft_id=info:pmid/8799558&rfr_iscdi=true